Corgenix announces establishment of bio-terrorism defense development program

28-Jan-2005

Corgenix Medical Corporation announced establishment of a program to develop a rapid detection system for viral hemorrhagic fevers, a disease category recognized and classified for its risk as potential agents of bioterrorism. Viral hemorrhagic fevers are included in the high priority "Category A" of biological diseases as defined by the Centers for Disease Control and Prevention (CDC). Along with anthrax, botulism, plague, smallpox and tularemia, viruses causing hemorrhagic fevers have been identified as key targets in the effort to understand and combat potential agents of bioterrorism.

In commenting about this new initiative in bio-terrorism defense diagnostics, Douglass Simpson, Corgenix President said, "This is a logical growth opportunity for Corgenix in a critical area that needs to be addressed on a national and international level. Bio-Terrorism Defense is a very important issue in this day and age, and we are confident that our collaboration with key industry and academic scientists will show meaningful results in a short period of time. We expect to present our program to the CDC, U.S. Department of Defense, and U.S. Department of Homeland Security, among other important government agencies and interested parties."

Other news from the department science

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures
View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures